Company overview
Inocras is a bioinformatics-led company providing whole genome sequencing and precision oncology solutions for cancer diagnosis and treatment selection. Their platforms include CancerVision for comprehensive genomic profiling and MRDVision for minimal residual disease detection with ultra-high sensitivity (1 ppm limit of detection). The company delivers actionable genomic insights, clinical trial matching, and germline/somatic variant analysis to support precision health and targeted therapy selection.
Whole Genome Sequencing & MRD Detection for Precision Oncology is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include whole genome sequencing, minimal residual disease detection, precision oncology, cancer genomics, mrd monitoring.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://inocras.com/
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- whole genome sequencing, minimal residual disease detection, precision oncology, cancer genomics, mrd monitoring
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What genomic testing capabilities does Inocras offer?
- Inocras offers target-enhanced whole genome sequencing (TE-WGS) through CancerVision, which analyzes the complete genomic makeup of cancer and identifies genetic changes including single nucleotide variants, copy number variants, gene fusions, microsatellite instability, and homologous recombination deficiency. The platform achieved 100% concordance with Illumina's TSO500 assay while identifying additional variants TSO500 missed.
- What is MRDVision and what sensitivity does it provide?
- MRDVision is Inocras's minimal residual disease detection platform that combines CancerVision whole genome profiling with Ultima Genomics' ppmSeq technology. It delivers a limit of detection as low as 1 ppm (0.0001%), providing 100-1,000x greater sensitivity than existing MRD assays by continuously scanning the entire genome rather than relying on pre-selected gene panels.
- What regulatory certifications and quality standards does Inocras maintain?
- Inocras operates a CLIA-certified and CAP-accredited laboratory, ensuring compliance with clinical laboratory standards. The company was founded in 2020 by physician-scientists, geneticists, and bioinformaticians and has developed IP-protected technology with proprietary whole genome insight platforms.
- Does Inocras provide clinical trial matching services?
- Yes, Inocras provides detailed clinical trial matching based on each patient's biomarkers, mutations, and pre-screening criteria for cancer patients. This service helps identify the best-matched clinical trials and potential treatment options tailored to individual patient genomic profiles.
- What AI capabilities has Inocras developed for oncology?
- Inocras developed a cancer foundation model trained on 2,882 whole genomes across diverse cancer types in collaboration with KAIST. The model uses learnable tokenization and genome-wide feature aggregation, achieving 98% accuracy for homologous recombination deficiency prediction and 84% accuracy for PAM50 subtype classification from DNA data alone.
Related editorial coverage
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Next-Generation Sequencing MEA: Impact on Precision Oncology Treatment Selection
- AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs
Explore lab tools and QA/QC resources for R&D teams.
